Table 1 Inclusion and exclusion criteria for participation in the quantitative study arm
Inclusion criteria: | |
1. | Initial diagnosis of a metastatic, incurable cancer (ICD 10 C 1–80 plus ICD 10 C 78–79) occurred within the last eight weeks, particularly: |
- non-small cell lung cancer (NSCLC) without epidermal growth factor (EFGR) mutations: met. NSCLC Stage IV – ICD C34.[01239] + metastasis code or C34.8 (multiple subdomains) + possibly M8012/3 (large cell carcinoma) | |
- met. esophageal carcinoma Stage IV – ICD C15.[123459] + metastasis code or C15.8 (multiple subdomains) + possibly M8070/3 (squamous cell carcinoma) | |
- met. stomach carcinoma Stage IV - ICD C16.[01234569] + metastasis code or C16.8 (multiple subdomains) + possibly M8145/3 (adenocarcinoma, diffuse) | |
- non-endocrine pancreas carcinoma Stage IV - ICD C25.[012379] + metastasis code or C25.8 (multiple subdomains) + possibly M8971/3 (pancreas blastoma) | |
- center-specific tumor entities | |
2. | Age ≥ 18 years |
3. | Ability to understand written and verbal questions in German |
4. | Willingness to participate in the study |
5. | Informed consent |
Exclusion criteria: | |
1. | Other hemato-oncological disease (e.g. leukemia) |
2. | Dementia |
3. | Psychosis/delirium |
4. | Major depression |